secwatch.observer — SEC 8-K summary
======================================

Issuer:     Adicet Bio, Inc. (ACET)
CIK:        0001720580
Form:       8-K
Filed at:   2023-06-26T23:59:59+00:00
Accession:  0000950170-23-029851
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adicet Bio ADI-001 Phase 1 shows 71% ORR; pivots to Phase 2 in 1H24
-------------------------------------------------------------------

- ADI-001 achieved 71% ORR & 63% CR across doses in heavily pre-treated NHL (median 4 prior lines; 50% post-CAR T).
- At RP2D (1B cells), CR rate 63%, 6-month CR rate 25%; in post-CAR T patients CR rate 67% (6-month CR 33%).
- No GvHD; only 1 Grade 3+ CRS and 1 Grade 3+ ICANS among 24 safety-evaluable patients.
- FDA Type B meeting completed; plan to start potentially pivotal Phase 2 in post-CAR T LBCL in 1H 2024.
- ADI-001 persistence at RP2D (Cmax 483 cells/µL day 9) exceeded approved autologous CD19 CAR T.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1720580/000095017023029851/0000950170-23-029851-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1720580/000095017023029851/acet-20230626.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-029851

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer